Could a cell infusion free liver transplant patients from lifelong drugs?

NCT ID NCT03164265

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether an infusion of special immune cells (regulatory dendritic cells) from the donor could help liver transplant recipients safely reduce their anti-rejection medications. Sixteen low-risk patients received the cell infusion a week before transplant, then followed a gradual drug-weaning schedule over a year. The goal was to see if some patients could achieve 'operational tolerance'—meaning their body accepts the new liver without needing long-term immunosuppression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Regulatory donor-derived dendritic cells (DCreg)
What this could lead to
If successful, this could allow some liver transplant recipients to reduce or stop taking lifelong anti-rejection drugs, improving quality of life and reducing side effects.
What could go wrong
This is an early-phase study with only 16 participants, so results may not apply broadly. There is a risk of organ rejection or serious infection if immunosuppression is reduced too much.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC

    Pittsburgh, Pennsylvania, 15261, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.